This invention concerns immune-activating oligonucleotides containing CpG motifs. Although it is known that certain CpG sequences can induce responses from human immune system cells, individual subjects show considerable heterogeneity in their response to different CpG sequences. These different responses make it difficult to induce a therapeutic immune response in all members of a diverse population using a single CpG sequence, even if such a sequence is repeated in a CpG oligonucleotide. The inventors have found that a broad-based immunomodulatory response can be generated in a wide cross-section of subjects by using a mixture of multiple different CpG motifs. The mixtures of oligodeoxynucleotides of the present invention can either be mixtures of different oligodeoxynucleotides expressing different CpG motifs or a single oligodeoxynucleotide containing multiple different motifs. The oligodeoxynucleotides of the current invention have the capacity to stimulate humoral, cell-mediated immune responses or both humoral and cell-mediated immune responses, depending on the motifs utilized.
Potential Commercial Applications:
The oligodeoxynucleotides of the present invention have uses including, but not limited to, treating allergies, infectious diseases, cancer, and autoimmune disorders; furthermore, the oligodeoxynucleotides of the present invention have utility as vaccine adjuvants for conventional and DNA vaccines, and as anti-sense therapeutics.
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
OTT Reference No: E-078-2000/1
Updated: August 9, 2015